Outset Medical reiterates $125M-$130M 2026 revenue guidance backed by $40M HCA refresh agreement (NASDAQ:OM)

Outset Medical (OM) reiterated its full-year 2026 revenue guidance of $125M–$130M during its Q2 earnings call, signaling management confidence in growth trajectory despite modest near-term quarterly results. The $31.6M revenue print reflects normalized operational scaling, while the 42.2% gross margin demonstrates pricing discipline and improving unit economics in the dialysis equipment and software space.

The $40M HCA refresh agreement represents a tangible validation of Outset's technology platform from one of North America's largest health systems operators. This multi-year partnership suggests sticky customer relationships and recurring revenue visibility, reducing execution risk around the forward guidance. HCA's scale-up order signals both competitive positioning and potential pathway to accelerated adoption across broader hospital networks.

Quarterly beat or miss is less material here than management's willingness to maintain—rather than raise—full-year targets. This conservative posture suggests either macro caution in healthcare capex cycles or recognition of near-term conversion headwinds offset by backlog confidence. The margin profile remains healthy for a mid-cap medical device operator in growth phase.

Sector implication: Medical device and healthcare IT subsectors benefit from institutional validation and recurring revenue models. OM's ability to land enterprise agreements while maintaining margins positions it favorably relative to pure-software healthcare names facing pricing pressure, though broader hospital utilization trends remain macro-dependent.